NOS inhibitors have been observed to attenuate PPI deficits mediated by DA receptor activation (amphetamine, methylphenidate) (Issy et al., 2009) or NMDARs antagonism (PCP) (Klamer et al., 2004; Fejgin et al., 2008) From a disease standpoint, multiple preclinical and clinical findings have linked increased NO signaling to pathophysiology of psychiatric disorders characterized by sensorimotor gating deficits including schizophrenia (Bernstein et al., 2001; Yao et al., 2004; Bernstein et al., 2005; Lauer et al., 2005; Nasyrova et al., 2015). The gene discussed is NOS1; the disease is schizophrenia.